Aspen Neuroscience, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ASPE | NGNE | LCTX | ALEC | DSGN | SLDB | |
|---|---|---|---|---|---|---|
| Market cap | 371.04M | 551.91M | 260.49M | 254.58M | 665.24M | 699.11M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -4.8 | -7.5 | -3.1 | -6.6 | -3.8 |
| Price/book | -0.6 | 2.0 | 4.3 | -25.6 | 3.0 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −17.46% | +3.45% | −40.46% | +75.38% | +54.73% | +54.69% |
| Today | +3.82% | +3.41% | +1.98% | +11.22% | +2.80% | +3.82% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ASPE news ›Latham Advises on Aspen Neuroscience’s US$140.6 Million IPO
Legal Desire Latham Advises on Aspen Neuroscience’s US$140.6 Million IPO Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson’s disease, ha
More from 1 other outlet
Aspen Neuroscience (ASPE): Large owner Arch Venture Partners Xiv, L.P. bought $18,000,000 worth of shares (1,200,000 units at $15.00) (SEC Form 4)
Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Aspen Neuroscience (ASPE): Large…
Aspen Neuroscience (ASPE): Executive Chair Hasnain Faheem converted options into 36,349 shares (SEC Form 4)
Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Aspen Neuroscience (ASPE):…
Aspen Neuroscience (ASPE): Director Spaventa Andrew converted options into 250,415 shares (SEC Form 4)
Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Aspen Neuroscience (ASPE): Director…
Aspen strikes R3.66bn deal for its menopause treatment
Europe-focused Ennogen will also buy related inventory valued at about €4m, Aspen said. As part of the deal, Aspen and Ennogen have long-term supply agreements under which Aspen will continue manufacturing and supplying the active…
Alto Neuroscience Inc (ANRO-N) Dividends
The Globe and Mail Instrument NameAlto Neuroscience IncInstrument Symbol(ANRO-N) Historical Dividends & Split More from The Globe
Parkinson’s disease biotech Aspen Neuroscience prices IPO at $15, the low end of the range
ASPE IPO News - Parkinson’s disease biotech Aspen Neuroscience prices IPO at $15, the low end of the range Renaissance Capital Aspen Neuroscience, a Phase 1/2a biotech developing stem cell therapies for Parkinsonâs disease, raised $141…
Aspen Neuroscience director reports IPO stock conversion
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease ReconAfrica Announces Grant of Stock Options to New Director Palantir…
Aspen Neuroscience closes IPO with about $141M gross
Palantir Reports Q3 2026 U.S. Comm Revenue Growth of 148% Y/Y and Revenue Growth of 96% Y/Y; Raises FY 2026 Revenue Guidance to 91% Y/Y Growth and U.S. Comm Revenue Guidance to 143% Y/Y, Crushing Consensus Expectations uniQure Announces…
Aspen Neuroscience: ARCH Venture Fund XIV buys 1.2M shares
ReconAfrica Announces Grant of Stock Options to New Director uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease Palantir…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com6
- tradingview.com6
- quantisnow.com4
- 247wallst.com3
- renaissancecapital.com3
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 47 articles, not a forecast.